Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

THC vs. CBD: What You Need to Know

With the rising demand of natural medicines, medical marijuana compounds THC and CBD are starting to make a name for themselves more than ever before. These two compounds have a wide range of health benefits, making it understandable why patients and physicians would be interested in this alternative treatment option. Although these two compounds are…
Read More

Medical Marijuana Faces Acceptance Barrier by Hesitant Medical Schools

A new study shows a growing interest by university pharmacy programs in teaching about medical marijuana in their curriculum, while medical schools seem to lag behind. Sixty-two percent of U.S. pharmacy school respondents queried in a new survey said they included medical marijuana in their doctorate of pharmacy curriculum. That’s according to a nine-page study co-authored by…
Read More

Customize Your Patient Notes with Arfinn Med

Joining the text messaging update, the Arfinn Med portal now presents the ability to create note taking templates. This innovative addition will allow physicians to streamline the data and information that they are collecting from patients, resulting in their cases staying aligned and concise. Additionally, through this function, physicians will be able to pick and…
Read More

Data Migration and Mapping Functions

Medical software does not have a good reputation for user experience and intuitive design. It can seem like a full-time job just learning how to use these software solutions.  In fact, according to a study from Stanford Medicine, 74% of doctors responded that their EMR increased the number of hours they work every day and…
Read More

New Feature: Calendar Integration

At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More

$2.7 million awarded for medical marijuana research in Colorado

The state has awarded $2.7 million for research into how medical marijuana could replace opioids to ease chronic spinal pain — and how it might treat irritability in children and adolescents with autism. Read the full story here.
Read More

Leave a Comment

You must be logged in to post a comment.